Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 6-Month Open Label Follow-Up Period
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2018
At a glance
- Drugs ANAVEX 2-73 (Primary) ; ANAVEX 2-73 (Primary) ; ANAVEX-2-73/donepezil (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Proof of concept
- Sponsors Anavex Life Sciences
- 16 Jan 2018 Results of a post-hoc analysis presented in an Anavex Life Sciences media release.
- 16 Jan 2018 According to an Anavex Life Sciences media release, post-hoc analysis of blood pressure data have been presented in The Journal of Clinical Hypertension.
- 04 Nov 2017 According to an Anavex Life Sciences media release, data from this trial were presented at the 2017 Clinical Trials on Alzheimer's Disease (CTAD) Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History